Launching DTC models requires navigating regulatory and licensing rules.
Spreeha Choudhury
Advertisement
Articles by Spreeha Choudhury
The idea of denying people proven medicines in the name of research has a dark legacy in this country.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Johnson and Johnson Reveals Plan to Separate Orthopaedics Business
2
The Most-Favored-Nation Policy: Outlook and Implications Beyond U.S.
3
Nabla Bio Enters $1 Billion Multi-Year Research Collaboration with Takeda
4
The Evolving Landscape in Psychiatry: Challenges and Opportunities for Biopharma
5
